Announcements

Seminar In Medicine, 19.07.2018, Dr. Neşe Ünver

Author: KUSOM
Time: 15:00
Location: MED 176

KOÇ UNIVERSITY

SCHOOL OF MEDICINE

 
SEMINAR IN MEDICINE
Thursday, July 19th,
 2018

 ******************************************************************
Speaker         :  Dr. Neşe Ünver, The University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Prevention-Research

Title               : Cell Biology to Translational Biology: Key Inflammatory Mediators as Biomarkers and Potential Therapeutic Targets

Time              : 15.00 (Refreshments will be served at 14:45)

Place              : MED 176

TelePresence   : AH 5th floor Chief Medical Officer / KUH 9th floor Meeting Room

**************************************************

CELL BIOLOGY TO TRANSLATIONAL BIOLOGY: KEY INFLAMMATORY MEDIATORS AS BIOMARKERS AND POTENTIAL THERAPEUTIC TARGETS

Inflammation, one of the hallmarks of cancer, is a known contributor to cancer initiation and progression. IL-6 differently modulates both tumor initiation and progression via activating STAT3 in a mouse model of lung cancer induced by the Kras oncogene. Besides its direct effect on tumor cell proliferation, IL-6 is also a major immunomodulatory agent, playing active roles in the regulation of acute phase reactions, inhibition of T regulatory (Tregs) cells and differentiation of B cells by orchestrating innate and adaptive immune responses. IL-6 family cytokines have been identified as cancer biomarkers through screening of inflammatory mediators in different fluids including saliva, serum, and bronchoalveolar lavage fluid (BALF). Our study highlighted that the chemopreventive effect of myo-inositol in a Kras-activated mouse model of lung premalignancy was associated with a reduction in IL-6 and phospho-STAT3 signaling, likely mediated by tumor-associated macrophages.

 

Development of monoclonal antibodies and small molecules in addition to defining de novo transcriptional regulators targeting trans-signaling of IL-6 would lead to an improvement in cancer therapeutic strategies. Unraveling the IL-6 family cytokines pathway in the tumor microenvironment and molecular characterization of cancer subtypes based on these key inflammatory mediators would enhance our understanding of chemoresistance and immunotherapy in cancer therapy.